Abbott EVP sells 885 shares in Form 4 filing

Abbott Laboratories executive Daniel Gesua Sive Salvadori, EVP and Group President, reported two share transactions.

Rhea-AI Filing Summary

Abbott Laboratories executive Daniel Gesua Sive Salvadori, EVP and Group President, reported two share transactions. On March 2, 2026, he executed an open-market sale of 885 common shares at $115.58 per share. On February 27, 2026, he disposed of 6,615 shares at $116.26 per share to satisfy tax-withholding obligations. Following these transactions, he directly holds 146,377 Abbott common shares.

Insider Trade Summary

Net Seller: 885 shares

Net Sell 2 txns

Insider Salvadori Daniel Gesua Sive

Role EVP AND GROUP PRESIDENT

Sold 885 shs ($102K)

Type	Security	Shares	Price	Value
Sale	Common shares without par value	885	$115.58	$102K
Exercise Price or Tax Liability	Common shares without par value	6,615	$116.26	$769K

Holdings After Transaction: Common shares without par value — 146,377 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Abbott Laboratories (ABT) report for Daniel Gesua Sive Salvadori?

Daniel Gesua Sive Salvadori reported one open-market sale and one tax-related share disposition. The Form 4 shows an 885-share sale on March 2, 2026, and a 6,615-share tax-withholding disposition on February 27, 2026, both involving Abbott common shares.

How many Abbott (ABT) shares did Daniel Gesua Sive Salvadori sell on the open market?

He sold 885 Abbott common shares in an open-market transaction. The sale occurred on March 2, 2026, at a reported price of $115.58 per share, as disclosed in the Form 4 insider trading report filed for Abbott Laboratories.

What is the 6,615-share transaction reported for Abbott (ABT) executive Daniel Gesua Sive Salvadori?

The 6,615-share transaction is a tax-withholding disposition. On February 27, 2026, shares were delivered at $116.26 per share to cover tax liabilities, rather than being a standard open-market sale, according to the Form 4 description of the transaction.

How many Abbott Laboratories (ABT) shares does Daniel Gesua Sive Salvadori hold after these transactions?

After the reported transactions, he directly holds 146,377 Abbott common shares. This post-transaction holding reflects the impact of both the 885-share open-market sale and the 6,615-share tax-withholding disposition disclosed in the Form 4.

What role does Daniel Gesua Sive Salvadori hold at Abbott Laboratories (ABT) in this Form 4?

He is identified as Abbott’s EVP and Group President. The Form 4 lists him as an officer, not a director or 10% owner, and reports his direct ownership transactions in Abbott common shares, including both a sale and a tax-withholding disposition.

What does the Form 4 filing for Abbott (ABT) reveal about transaction types for Daniel Gesua Sive Salvadori?

The filing shows an open-market sale and a tax-withholding share delivery. Code “S” denotes an open-market sale of 885 shares, while code “F” indicates 6,615 shares used to pay tax obligations by delivering securities instead of cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 08:10 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Salvadori Daniel Gesua Sive

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP AND GROUP PRESIDENT

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	02/27/2026		F		6,615	D	$116.26	147,262	D
Common shares without par value	03/02/2026		S		885	D	$115.58	146,377	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Daniel Gesua Sive Salvadori by Jessica H. Paik, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.